Several other analysts also recently issued reports on the company. SVB Leerink downgraded Silverback Therapeutics from an outperform rating to a market perform rating in a research note on Friday, April 1st. HC Wainwright downgraded Silverback Therapeutics from a buy rating to a neutral rating in a research note on Friday, April 1st. The Goldman Sachs Group downgraded Silverback Therapeutics from a buy rating to a neutral rating in a research note on Friday, April 1st. Zacks Investment Research raised Silverback Therapeutics from a hold rating to a buy rating and set a $3.75 price objective on the stock in a research note on Wednesday, April 6th. Finally, Jonestrading downgraded Silverback Therapeutics from a buy rating to a hold rating in a research report on Friday, April 1st. Five equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of Hold and an average target price of $27.15.
SBTX traded down $0.07 on Friday, hitting $2.96. 358,537 shares of the company’s stock traded hands, compared to its average volume of 359,440. The company’s 50 day simple moving average is $3.42 and its 200-day simple moving average is $5.09. Silverback Therapeutics has a one year low of $2.80 and a one year high of $35.63.
Silverback Therapeutics Company Profile (Get Rating)
Silverback Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers.
- Get a free copy of the StockNews.com research report on Silverback Therapeutics (SBTX)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Want More Great Investing Ideas?
- 3 Stocks to DOUBLE This Year
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 9 "MUST OWN" Growth Stocks
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.